Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
FibroGen, Inc. is a biopharmaceutical company focused on developing therapies for anemia and cancer. Its key products include roxadustat, an oral treatment for anemia in chronic kidney disease and myelodysplastic syndromes, and FG-3246, an antibody-drug conjugate targeting cancer. The company collaborates globally, with a core business model centered on drug development, licensing, and strategic partnerships in markets like China, Europe, and Japan.
This description was generated via AI from an annual report. Updated about 1 year ago.